Menu
← Oncology Approval Tracker
FDA DECISION ·
Vitrakvi
larotrectinib · Bayer Healthcare Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children with NTRK fusion-positive solid tumors without a known acquired resistance mutation, when disease is metastatic or surgery would likely cause severe morbidity, and no satisfactory alternatives exist or disease has progressed following treatment.
LAMPGEN ANALYSIS
Why it matters
Additional clinical follow-up supported traditional approval of this tumor-agnostic indication originally authorized in 2018.
What research teams should watch
Review the actual fusion and prior treatment or surgical assessment, and preserve continuity between molecular testing and referral.
PRIMARY RECORDS